LAVAL, Quebec—Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) reported revenue of $2.7 billion for the second quarter ending June 30, 2015, a 34 percent increase over the same period of the previous year.

“We once again exceeded our guidance and delivered our fourth consecutive quarter of greater than 15 percent organic growth,” said J. Michael Pearson, chairman and chief executive officer. “Our strong second quarter results were driven by out performance in our U.S. businesses, strong results in certain emerging markets and outstanding starts to both the Salix and Dendreon acquisitions.”

Operating income of $341.5 million for the quarter was down 3.8 percent when compared with operating income of $355.1 million for the same quarter of the prior year. Net loss of $53.0 million for the second quarter of 2015 compares with net income of $125.8 million for Q2 2014.

Same store sales organic growth of 19 percent was driven in part by contact lenses as well as dental, dermatology and Obagi skin care products.

Contact lens sales specifically were up 22 percent in the second quarter of 2015, rising from $42.1 million in the second quarter of 2014 to $51.2 million during the second quarter of 2015.

For the six months ending June 30, 2015, total revenues were $4.9 billion, up 26 percent from the first half of 2014; operating income of $884.9 million for the first half of 2015 was up 24 percent when compared with the same period of 2014; and net income of $20.7 million for the first six months of 2015 was down 80 percent from net income of $103.2 in the same period of 2014.

Contact lens sales for the first half of 2015 were up 19 percent, increasing from $83.0 million during the first six months of 2014 to $98.9 million in the same period of 2015. “BioTrue grows four times faster than its category,” the company said about the Bausch + Lomb contact lens line during a conference call with investors.

This month Valeant announced its agreement to acquire Unilens Vision Inc., manufacturer of C-Vue brand contact lenses, and in 2013 the company acquired contact lens supplier Bausch + Lomb. “We have improved Bausch + Lomb from 2 percent to 9 percent organic growth since its acquisition,” the company said during the conference call.

Regarding the contact lens market globally, the company said: “We are gaining share in contact lenses, a category that has a number of great companies competing. We’ve been lucky with some great new products, Bausch + Lomb’s Biotrue OneDay and Ultra, and we also reorganized our business into local teams. We launched Biotrue daily in China, and it’s really taking off. It’s a combination of some great products and a really focused team. Eyecare professionals, especially in the contact lens area, realize that Bausch + Lomb is back in the market.”